New pill shows promise for rare blood cancer in early trial
NCT ID NCT05141682
First seen Nov 10, 2025 · Last updated Jun 17, 2026 · Updated 34 times
Summary
This study tests an oral chemotherapy drug called CC-486 (azacitidine) in 11 adults with a rare type of leukemia (T-LGLL) that has returned or not responded to prior treatments. The goal is to find the best dose and see if the drug can shrink or control the cancer. Participants will be monitored for side effects and how long any benefits last.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T-CELL LARGE GRANULAR LYMPHOCYTE LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
University of Virginia
Charlottesville, Virginia, 22908, United States
Conditions
Explore the condition pages connected to this study.